PRGN-2012 is an adenovirus vector-based gene therapy expected to induce immune responses against HPV 6 or 11 infected cells. Findings showed among those treated at the recommended PRGN-2012 dose ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain ...

The most common form of hereditary deafness in humans is caused by mutations in the GJB2 gene, which encodes the gap junction protein connexin 26. That regulates the transport of potassium and ...

OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global ...

and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform. GQ Bio is a privately held biopharmaceutical company with a novel, high-capacity ...

Pacira (PCRX) announced it has acquired the remaining 81% equity stake of GQ Bio Therapeutics for approximately $32M, net of working capital ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in ...

Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...